1. Home
  2. CWEN vs TNGX Comparison

CWEN vs TNGX Comparison

Compare CWEN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearway Energy Inc. Class C

CWEN

Clearway Energy Inc. Class C

N/A

Current Price

$28.54

Market Cap

3.7B

Sector

Utilities

ML Signal

N/A

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

N/A

Current Price

$21.75

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CWEN
TNGX
Founded
2012
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.1B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
CWEN
TNGX
Price
$28.54
$21.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
13
Target Price
$40.36
★ $47.00
AVG Volume (30 Days)
1.4M
★ 3.6M
Earning Date
11-09-2026
11-09-2026
Dividend Yield
★ 6.27%
N/A
EPS Growth
11.94
★ 26.89
EPS
★ 0.75
N/A
Revenue
★ $1,429,000,000.00
$62,384,000.00
Revenue This Year
$20.96
N/A
Revenue Next Year
$13.30
N/A
P/E Ratio
$41.03
★ N/A
Revenue Growth
4.23
★ 48.29
52 Week Low
$28.57
$8.30
52 Week High
$41.74
$34.39

Technical Indicators

Market Signals
Indicator
CWEN
TNGX
Relative Strength Index (RSI) 31.64 44.62
Support Level N/A $20.49
Resistance Level $30.98 $22.01
Average True Range (ATR) 1.34 1.92
MACD -0.64 -0.15
Stochastic Oscillator 0.40 18.52

Price Performance

Historical Comparison
CWEN
TNGX

About CWEN Clearway Energy Inc. Class C

Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and the owner of modern, sustainable, and long-term contracted assets across North America. The company segments its operations into Flexible Generation, Renewables & Storage, and Corporate divisions. The majority of its revenue is generated from the Renewables & Storage segment.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: